MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more than analysts expected, as the drugmaker prepares for the loss of exclusivity for several of its drugs. MSD reported fourth-quarter global sales of $16.4 billion, an increase of 5% from the same period in 2024….